Etoposide Can be Safely Eliminated in Pediatric Acute Myeloid Leukemia

Removing etoposide from frontline induction chemotherapy did not appear to negatively affect key outcomes for patients with pediatric acute myeloid leukemia (AML), according to recent findings from a Children’s Oncology Group (COG) clinical trial presented at the ASH Annual Meeting 2025.

Read more: https://www.cancertherapyadvisor.com/reports/etoposide-safely-eliminated-pediatric-acute-myeloid-leukemia/